SemBioSys Genetics Inc.
About SemBioSys Genetics
Calgary, Alberta-based SemBioSys is focused on leveraging its unique proprietary platform to manufacture high-value proteins and oils. SemBioSys’ seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company’s current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AI Milano, a next-generation cardiovascular therapy. SemBioSys' proprietary safflower-derived Apo AIMilano is a des-1,2- variant of Apo AI Milano as previously described in the literature. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS.
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of SemBioSys Genetics
News about SemBioSys Genetics
Here you will find SemBioSys Genetics Inc.
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
